TAMOXIFEN SCP tamoxifen (as citrate) 20 mg tablet blister pack

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

tamoxifen citrate, Quantity: 30.34 mg (Equivalent: tamoxifen, Qty 20 mg)

MAH:

Southern Cross Pharma Pty Ltd

pharmaceutical_form:

Tablet

composition:

Excipient Ingredients: brilliant scarlet 4R; maize starch; lactose monohydrate; magnesium stearate; povidone

administration_route:

Oral

units_in_package:

60, 30

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

Treatment of breast cancer TAMOXIFEN SCP is indicated for the treatment of breast cancer.,Primary reduction of breast cancer risk TAMOXIFEN SCP is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

leaflet_short:

Visual Identification: Pink, round biconvex tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

authorization_status:

Registered

authorization_date:

2020-07-24